Published in J Cancer on June 23, 2015
Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev (2016) 0.91
Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness. Histochem Cell Biol (2016) 0.78
M2 tumour-associated macrophages contribute to tumour progression via legumain remodelling the extracellular matrix in diffuse large B cell lymphoma. Sci Rep (2016) 0.77
Dermal fibroblasts induce cell cycle arrest and block epithelial-mesenchymal transition to inhibit the early stage melanoma development. Cancer Med (2016) 0.77
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Oncotarget (2016) 0.76
Varying effects of EGF, HGF and TGFβ on formation of invadopodia and invasiveness of melanoma cell lines of different origin. Eur J Histochem (2016) 0.75
Use of a Tissue Engineered Human Skin Model to Investigate the Effects of Wounding and of an Anti-Inflammatory on Melanoma Cell Invasion. PLoS One (2016) 0.75
The Expression and Relationship of CD68-Tumor-Associated Macrophages and Microvascular Density With the Prognosis of Patients With Laryngeal Squamous Cell Carcinoma. Clin Exp Otorhinolaryngol (2016) 0.75
Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. J Control Release (2016) 0.75
Fibroblasts in cancer. Nat Rev Cancer (2006) 18.95
Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res (1999) 8.63
Mechanisms of cancer drug resistance. Annu Rev Med (2002) 7.91
Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol (2006) 7.76
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer (2004) 6.47
The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol (2012) 6.07
Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med (2011) 5.54
Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res (2008) 5.21
Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature (2013) 4.90
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst (2003) 3.65
Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist (2011) 2.89
Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem (2007) 2.81
Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest (2009) 2.66
Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest (2006) 2.64
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med (2014) 2.50
N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res (2001) 2.47
Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med (2008) 2.40
E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-related adhesion receptors. Am J Pathol (2000) 2.36
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res (2005) 2.28
Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res (2011) 2.26
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol (2009) 2.25
Activation of fibroblasts in cancer stroma. Exp Cell Res (2010) 2.19
Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res (2002) 2.06
Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem (2001) 1.98
Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci (Landmark Ed) (2010) 1.87
Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene (2004) 1.83
Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem (2005) 1.81
Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther (2008) 1.79
Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol (2014) 1.71
Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol (2006) 1.67
Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem (2003) 1.61
Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets (2005) 1.59
E-cadherin is the major mediator of human melanocyte adhesion to keratinocytes in vitro. J Cell Sci (1994) 1.59
CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. Cancer Res (2003) 1.57
Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci U S A (1991) 1.54
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol (2010) 1.42
Transforming growth factor-beta1 increases survival of human melanoma through stroma remodeling. Cancer Res (2001) 1.40
Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 1.36
Drug resistance in melanoma: mechanisms, apoptosis, and new potential therapeutic targets. Cancer Metastasis Rev (2001) 1.36
CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci U S A (2009) 1.35
Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer (2013) 1.34
Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res (2005) 1.33
Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death. Int J Mol Sci (2012) 1.32
Cancer associated fibroblasts stimulated by transforming growth factor beta1 (TGF-beta 1) increase invasion rate of tumor cells: a population study. Breast Cancer Res Treat (2007) 1.32
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem (2012) 1.31
Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Arzneimittelforschung (2008) 1.30
The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. Cancer (2013) 1.28
Melanoma and the tumor microenvironment. Curr Oncol Rep (2008) 1.26
Molecular biology of cancer-associated fibroblasts: can these cells be targeted in anti-cancer therapy? Semin Cell Dev Biol (2009) 1.23
Sunitinib therapy for melanoma patients with KIT mutations. Clin Cancer Res (2012) 1.23
Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol (2013) 1.20
Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci (2008) 1.20
Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci U S A (1992) 1.20
The good and the bad of chemokines/chemokine receptors in melanoma. Pigment Cell Melanoma Res (2009) 1.18
Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer (2008) 1.17
Fibroblasts contribute to melanoma tumor growth and drug resistance. Mol Pharm (2011) 1.17
Drug-resistance in human melanoma. Int J Cancer (2001) 1.15
Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol (Paris) (2005) 1.15
Modulated expression of WFDC1 during carcinogenesis and cellular senescence. Carcinogenesis (2008) 1.13
Mesenchymal CD44 expression contributes to the acquisition of an activated fibroblast phenotype via TWIST activation in the tumor microenvironment. Cancer Res (2013) 1.12
On the origin of cancer-associated fibroblasts. Cell Cycle (2009) 1.11
HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. Oncogene (2005) 1.11
Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle (2005) 1.10
Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma. Oncologist (2013) 1.08
Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol (2012) 1.08
c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol (2009) 1.08
BRAF inhibitors in cancer therapy. Pharmacol Ther (2013) 1.07
Gene expression profiling reveals cross-talk between melanoma and fibroblasts: implications for host-tumor interactions in metastasis. Cancer Res (2005) 1.06
CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells (2014) 1.04
Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2. J Dermatolog Treat (2013) 1.03
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability. Mol Cancer Ther (2012) 1.02
Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer. PLoS One (2013) 1.01
Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell (2009) 1.01
MMP13 mediates cell cycle progression in melanocytes and melanoma cells: in vitro studies of migration and proliferation. Mol Cancer (2010) 1.01
Carcinoma-associated fibroblasts are a promising therapeutic target. Cancers (Basel) (2013) 1.01
Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol (2000) 0.98
KIT as a therapeutic target in melanoma. J Invest Dermatol (2010) 0.97
Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol Cancer Res (2009) 0.97
Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM). Br J Cancer (2002) 0.97
Stromal cells and integrins: conforming to the needs of the tumor microenvironment. Neoplasia (2009) 0.95
Fibroblast activation protein: A potential therapeutic target in cancer. Cancer Biol Ther (2012) 0.95
Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol (2014) 0.94
Activation of Notch1 signaling in stromal fibroblasts inhibits melanoma growth by upregulating WISP-1. Oncogene (2011) 0.93
Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol (2003) 0.92
E- to N-cadherin switch in melanoma is associated with decreased expression of phosphatase and tensin homolog and cancer progression. Br J Dermatol (2013) 0.92
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma. Cancer Immunol Immunother (2011) 0.91
Stromal fibroblasts synergize with hypoxic oxidative stress to enhance melanoma aggressiveness. Cancer Lett (2012) 0.91
The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer (2009) 0.91
The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer (2001) 0.90
Mitochondrial Oxidative Stress due to Complex I Dysfunction Promotes Fibroblast Activation and Melanoma Cell Invasiveness. J Signal Transduct (2012) 0.90
Beneficial effects of RAF inhibitor in mutant BRAF splice variant-expressing melanoma. Mol Cancer Res (2014) 0.89
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol (2012) 0.89
The architecture of fibroblast monolayers of different origin differentially influences tumor cell growth. Int J Cancer (2012) 0.88